Loading...
Market
Outcome of Keros Therapeutics TROPOS trial by Q2 2025?
2
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial halted • 25%
Keros Therapeutics official press releases or regulatory filings
Story
Keros Therapeutics Halts Dosing in Phase 2 PAH Trial Due to Safety Concerns
Dec 12, 2024, 12:02 PM
Keros Therapeutics Inc. (Nasdaq: KROS) has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms of its ongoing Phase 2 TROPOS trial due to safety concerns related to pericardial effusion adverse events. The trial, which evaluates cibotercept (KER-012) in combination with background therapy for patients with pulmonary arterial hypertension (PAH), remains fully enrolled. Dosing in the 1.5 mg/kg treatment arm continues following a risk and benefit assessment by the independent Data Monitoring Committee (DMC). The company has informed investigators and regulatory authorities, including the FDA, of this decision and plans to present topline data from all treatment arms in the second quarter of 2025. Shares of Keros Therapeutics plunged following the announcement.
View original story
Similar markets
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Yes • 50%
No • 50%
Safety established • 25%
Preliminary efficacy demonstrated • 25%
Both safety and efficacy demonstrated • 25%
No significant results • 25%
Positive results for another indication • 25%
Negative results across all indications • 25%
Inconclusive results • 25%
Not published by this date • 25%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Yes • 50%
No • 50%
Clinical hold • 25%
No action • 25%
Request for additional data • 25%
Other • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial extended • 25%